Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Impact of Prosthesis-Patient Mismatch on Long-Term Survival in Patients With Small St Jude Medical Mechanical Prostheses in the Aortic Position
Mohty-Echahidi, Dania, Malouf, Joseph F., Girard, Steve E., Schaff, Hartzell V. , Grill, Diane E. , Miller, Fletcher A., Girard, Steven , Enriquez‐Sarano, Maurice , Enriquez-Sarano, Maurice , Schaff, Hartzell

Mayo Clinic

Circulation | January 16, 2006 | Volume: 113 | Issue: 3 | Pages: 420-426

10.1161/circulationaha.105.546754 | PMID 16415379 Get It

Background— The impact of aortic prosthesis-patient mismatch (P-PtM) on long-term survival is unclear. Methods and Results— Between 1985 and 2000, 388 patients at Mayo Clinic in Rochester, Minn, underwent aortic valve replacement (AVR) with 19- or 21-mm St Jude Medical prostheses and had transthoracic echocardiography within 1 year after AVR. Mean age of patients was 62±13 years; 69% were female. Prosthesis effective orifice area (EOA) was derived from the continuity equation. P-PtM was classified as severe (indexed EOA ≤0.60 cm 2 /m 2 ), moderate (0.60 cm 2 /m 2 <indexed EOA≤0.85 cm 2 /m 2 ), or not hemodynamically significant (indexed EOA >0.85 cm 2 /m 2 ). P-PtM was severe in 66 patients (17%), moderate in 168 (43%), and not hemodynamically significant in 154 (40%). Patients with severe P-PtM had a significantly larger body surface area ( P <0.0001), higher mean gradient ( P <0.0001), lower preoperative ( P <0.0001) and postoperative ( P <0.0001) ejection fractions, and lower stroke volume ( P <0.0001) and more often received a 19-mm prosthesis ( P =0.0008) than patients with moderate or no hemodynamically significant mismatch. For patients with severe mismatch, 5-year survival rates (72±6%) and 8-year survival rates (41±8%) were significantly less than for patients with moderate mismatch (80±3% and 65±5%; P =0.026) or no hemodynamically significant mismatch (85±3% and 74±5%; P =0.002). On multivariate analysis after adjustment for other predictors of outcome, severe mismatch was associated with higher mortality (hazard ratio 2.18; 95% confidence interval 1.24 to 3.85; P =0.007) and higher incidence of congestive heart failure (hazard ratio 3.1; 95% confidence interval 1.3 to 7.4; P =0.009) than no hemodynamically significant mismatch. Conclusions— Severe P-PtM is an independent predictor of higher long-term mortality and congestive heart failure in patients with small St Jude Medical aortic valve prostheses. For patients undergoing AVR who are at risk of severe mismatch, every effort should be made to use a larger prosthesis or to consider a prosthesis with a larger EOA.
Female urology
Petrou, Steven P.

Mayo Clinic

International braz j urol | January 10, 2006 | Volume: 30 | Issue: 6 | Pages: 531-532

10.1590/s1677-55382004000600021 Get It

Female urology
Petrou, Steven P., Petrou, Steven P.

Mayo Clinic

International braz j urol | January 10, 2006 | Volume: 31 | Issue: 1 | Pages: 88-90

10.1590/s1677-55382005000100022 Get It

Ureteral endometriosis and coexistent urethral leiomyoma in a postmenopausal woman
Strang, A., Lisson, Scott W., Petrou, Steven P., Petrou, Steven P.

Mayo Clinic

International braz j urol | January 10, 2006 | Volume: 30 | Issue: 6 | Pages: 496-498

10.1590/s1677-55382004000600008 | PMID 15663808 Get It

Female urology
Petrou, Steven P.

Mayo Clinic

International braz j urol | January 9, 2006 | Volume: 31 | Issue: 2 | Pages: 181-183

10.1590/s1677-55382005000200022 Get It

Female urology
Petrou, Steven P.

Mayo Clinic

International braz j urol | January 9, 2006 | Volume: 31 | Issue: 3 | Pages: 288-290

10.1590/s1677-55382005000300023 Get It

Female Urology
Petrou, Steven P., Petrou, Steven P.

Mayo Clinic

International braz j urol | January 9, 2006 | Volume: 31 | Issue: 4 | Pages: 409-411

10.1590/s1677-55382005000400023 Get It

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Dispenzieri, Angela , Lacy, Martha Q. , Katzmann, Jerry A., Rajkumar, S. Vincent , Abraham, Roshini S. , Hayman, Suzanne R. , Kumar, Shaji , Clark, Raynell, Kyle, Robert A. , Litzow, Mark R. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana M., Porrata, Luis F. , Elliott, Michelle A. , Johnston, Patrick B. , Greipp, Philip R., Zeldenrust, Steven R., Gastineau, Dennis A., Witzig, Thomas E. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | January 6, 2006 | Volume: 107 | Issue: 8 | Pages: 3378-3383

10.1182/blood-2005-07-2922 | PMID 16397135 Get It

AbstractThe immunoglobulin free light chain (FLC) is the precursor protein of amyloid in primary systemic amyloidosis (AL). Historically, the ability to monitor the amyloid protein precursor protein has been crude. We evaluated the utility of the FLC assay in a retrospective analysis of patients with AL undergoing peripheral blood stem cell transplantation (PBSCT). Ninety-three such patients had serial FLC measurements performed. The prognostic effects of the initial concentration and the extent of reduction of monoclonal FLC on survival were studied. There was a significantly higher risk of death in patients with higher baseline FLC (hazard ratio 2.6, P < .04). Baseline FLC correlated with serum cardiac troponin levels, and higher FLC levels were associated with more organs involved by amyloid, suggesting that high FLC levels may be associated with more advanced disease. The percent FLC reduction did not predict for survival, but the absolute level of FLC achieved after therapy did. Normalization of FLC level after PBSCT predicted for both organ response and complete hematologic response. Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome.
RATE OF RECURRENT STRESS URINARY INCONTINENCE AFTER RETROPUBIC URETHROLYSIS
Petrou, Steven P. , Young, Paul R.

Mayo Clinic

Journal of Urology | January 5, 2006 | Volume: 167 | Issue: 2 Part 1 | Pages: 613-615

10.1016/s0022-5347(01)69096-7 | PMID 11792929 Get It

Clinical implication of centrosome amplification in plasma cell neoplasm
Ahmann, Greg, Henderson, Kim, Santana-Dávila, Rafael , Greipp, Philip R., Lacy, Martha Q. , Dispenzieri, Angela , Kumar, Shaji , Rajkumar, S. Vincent , Lust, John A., Kyle, Robert A. , Zeldenrust, Steven R., Hayman, Suzanne R. , Fonseca, Rafaël , Chng, Wee Joo , Henderson, Kimberly J., Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | December 23, 2005 | Volume: 107 | Issue: 9 | Pages: 3669-3675

10.1182/blood-2005-09-3810 | PMID 16373658 Get It

The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability in a variety of tumors and is a potential mechanism causing aneuploidy in MM. Using immunofluorescent (IF) staining, centrosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS). We also investigated the gene expression of centrosome proteins. Overall, gene expression data correlated well with IF-detected centrosome amplification, allowing us to derive a gene expression-based centrosome index (CI) as a surrogate for centrosome amplification. Clinically, MM patients with high CI (> 4) are associated with poor prognostic genetic and clinical subtypes (chromosome 13 deletion, t(4; 14), t(14;16), and PCLI > 1%, P < .05) and are shown here to have short survival (11.1 months versus 39.1 months, P < .001). On multivariate regression, a high CI is an independent prognostic factor. Given that centrosome amplification is already observed in MGUS and probably integral to early chromosomal instability and myeloma genesis, and patients with more extensive centrosome amplification have shorter survival, the mechanisms leading to centrosome amplification should be investigated because these may offer new avenues for therapeutic intervention.